| Christian Angermayer |
Christian Berthold Angermayer founded Alnylam Europe AG in 2000, ATAI Life Sciences AG in 2018, Presight Capital Management Co LLC in 2018, and various other companies. Mr. Angermayer also founded Apeiron Investment Group AG, Samara Asset Group Plc, North American Council For Online Learning Ltd., and various other companies. Mr. Angermayer also currently works at Enhanced Group, Inc., as Chairman, Centenara Labs AG, as Director, Frontier Acquisition Corp., as Chief Executive & Director, and various other companies. Mr. Angermayer also formerly worked at Deutsche Maklerservice AG, as Director-Supervisory Board from 2004 to 2007, C-QUADRAT Investment AG, as Director-Supervisory Board from 2006 to 2008, VCH Investment Group AG, as Director-Management Board from 2005 to 2006, and various other companies. Mr. Angermayer received his undergraduate degree from the University of Bayreuth. |
| Srinivas Rao |
Srinivas G. Rao was the founder of Kyalin Biosciences, Inc. founded in 2011, serving as Chief Executive Officer from 2011 to 2013. Dr. Rao is the founder of ATAI Life Sciences AG founded in 2018, serving as Chief Scientific Officer since 2018. Dr. Rao is the founder of Kures, Inc. founded in 2019, serving as Chief Scientific Officer since 2022. Dr. Rao was the founder of Atai Beckley NV founded in 2018, serving as Co-Chief Executive Officer in 2024. Dr. Rao is also the founder of IntroSpect Digital Therapeutics, Inc... Dr. Rao is Chief Executive Officer at EntheogeniX Biosciences, Inc. since 2019. Dr. Rao is Chief Executive Officer & Director at Atai Beckley, Inc. starting 2025. Dr. Rao is Director at Perception Neuroscience, Inc. Dr. Rao is Member of Society For Neuroscience. Dr. Rao is Member of American College of Neuropsychopharmacology. Former positions include Chief Scientific Officer & Director-Science at Cypress Bioscience, Inc. from 2000 to 2009. Non-Executive Director at Bionomics Ltd. from 2020 to 2021. Director at IntelGenx Technologies Corp. from 2021 to 2023. Director at AVACEN, Inc. Chief Medical Officer & Senior Vice President at Assertio Therapeutics, Inc. from 2014 to 2017. Member of American Pain Society. Member of International Association for the Study of Pain. Chief Scientific Officer at Sova Pharmaceuticals, Inc. Executive VP & Head-Neuroscience Division at Travere Therapeutics, Inc. from 2013 to 2014. Chief Medical Officer at Vertero Therapeutics, Inc. from 2017 to 2019. Chief Medical Officer at GABA Therapeutics, Inc. Education includes doctorate degrees from Yale School of Medicine and Yale Graduate School of Arts & Sciences. |
| Gerd G. Kochendoerfer |
Gerd G. Kochendoerfer is currently Chief Operating Officer at NFlection Therapeutics, Inc. since 2021 and Chief Operating Officer at Atai Beckley, Inc. since 2024. Former positions include Senior Director-Drug Development at Kyntra Bio, Inc. from 2005 to 2008, Director-Research & Development at Gryphon Therapeutics, Inc., Vice President-Pharmaceutical Development at Assertio Therapeutics, Inc. from 2011 to 2013, Senior Vice President & Head of Operations at PellePharm, Inc., and Chief Operating Officer at Atai Beckley NV. Education includes a doctorate from the University of California, Berkeley. |
| Kevin James Craig |
Kevin Craig is currently Chief Medical Officer at Atai Beckley, Inc. since 2025. Formerly, Dr. Craig was Vice President-Clinical Development at Atai Beckley NV from 2021 to 2025, Head-Early Clinical Development at Jazz Pharmaceuticals, Inc., and Senior Director-Neuroscience at Labcorp Drug Development, Inc. Education includes graduate degrees from the University of Cambridge and the University of the Witwatersrand. |
| Glenn Frank Short |
Glenn Short is currently Chief Executive Officer at EmpathBio, Inc. and Atai Therapeutics, Inc. Dr. Short is also Chief Scientific Officer at Atai Beckley, Inc. starting in 2025. Formerly, Dr. Short was VP-Research & Translational Development at Flex Pharma, Inc. and Chief Scientific Officer at Atai Beckley NV. Education includes undergraduate and doctorate degrees from the University of Virginia. |
| Michael E. Faerm |
Michael E. Faerm is currently Chief Financial Officer at Atai Beckley, Inc. since 2026. Former positions include Chief Financial Officer at Harpoon Therapeutics, Inc. from 2023 to 2024, Chief Financial & Accounting Officer at Viracta Therapeutics, Inc. from 2024 to 2025, Chief Financial Officer at Artiva Biotherapeutics, Inc. from 2021 to 2023, Chief Business Officer & Senior Vice President at Innoviva, Inc. from 2015 to 2018, Vice President at Merrill Lynch & Co., Inc. in 2000, Associate Director at Forest Laboratories, Inc. in 2006, Associate Director at Regeneron Pharmaceuticals, Inc. in 2004, Analyst at Credit Suisse Securities (USA) LLC from 2011 to 2013, and Analyst at Wells Fargo Securities LLC. Education includes undergraduate studies at The Trustees of Columbia University in The City of New York, graduate studies at Stanford University, and an MBA from Harvard Business School. |
